HONG KONG, Aug. 30, 2025 -- LifeTech Scientific Corporation ("LifeTech" or the "Company", together with its subsidiaries, the "Group", stock code: 1302.HK), a medical device company specializing in minimally invasive interventional solutions for cardio-cerebrovascular and peripheral vascular diseases, today announced its unaudited consolidated results for the six months ended 30 June 2025 (the "Reporting Period"). Revenue Growth: The Group achieved revenue of approximately RMB676.7 million during the Reporting Period, repres
BEIJING and SHANGHAI and BOSTON, Aug. 30, 2025 -- Jacobio Pharma (1167.HK) today announced its interim results for the six months ended June 30, 2025. During the reporting period, the Company achieved revenue of RMB45.7 million, representing a 100% increase compared with the same period in 2024. Research and development (R&D) expenses amounted to RMB93.2 million. The net loss for the first half of 2025 was RMB59.0 million, narrowing by 65.1% compared with the same period in 2024. As of June 30, 2025, Jacobio maintained cash and bank balances, and investments in capital protected
GALWAY, Ireland, Aug. 29, 2025 -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the following investor conferences: 2025 Wells Fargo Healthcare Conference Thursday, September 4, 2025, at 8:00 a.m. EDT (7:00 a.m. CDT)Geoff Martha, Medtronic chairman and chief executive officer, and Thierry Piéton, Medtronic executive vice president and chief financial officer, will answer questions on the company. Morgan Stanley 23rd Annual Global Healthcare ConferenceMonday, September 8, 2025, at 4:50 p.m. EDT (3:50 p.m.
NEW YORK, Aug. 29, 2025 -- Since its launch, Lifezoom's light therapy devices have steadily become a promising contender in the industry. However, users' feedback revealed that the original single blue light mode is primarily suitable for short-term use, which highlights the limited benefits of blue light, with most customers calling for higher efficiency at specific wavelengths. As Lifezoom's CEO mentioned, "User feedback is our most important guide. In this instance, we acted quickly to enhance the red light wand, reflecting Lifezoom's core philosophy of putting user needs at th
[ 메디채널 황정호 기자 ] -- 기대수명 예측 정확성에 대한 투명성 촉구 -- 라페터스의 폐업이 임박함에 따라 영업비밀 보호 주장 근거 소멸 주장 탤러해시, 플로리다주, 2025년 8월 29일 -- 사망보험금 유동화(life settlement) 시장 선도기업 코벤트리 퍼스트 LLC(Coventry First LLC, 이하 '코벤트리')가 금주 법으로 규정된 기대수명 감사 보고서 공개를 막으려는 라페터스 솔루션스(Lapetus Solutions, 이하 '라페터스')의 시도에 반대하는 법적 답변서를 제출했다. 이번 대응 조치로 코벤트리는 사망보험금 유동화 시장의 건전성을 유지하기 위해서는 정확하고 투명한 기대수명 추정치가 반드시 필요하다는 기존 입장을 재확인했다. 이와 동시에 코벤트리는 라페터스가 2025년 8월 31일 폐업을 발표한 만큼 영업비밀 보호 주장은 더 이상 성립하지 않는다는 주장이 담긴 약식판결 신청서도 자체적으로 제출했다. 플로리다주 법에 따르면 기대수명 산정기관은 각 감사 이전 5개 연도에 대한 3년 주기 기대수명 감사 보고서를 플로리다 보험 규제국(Office of Insurance Regulat
HONG KONG, Aug. 29, 2025 -- On the morning of 29 August, Guo Guangchang, Chairman of Fosun International, stated at the Company's 2025 interim results presentation that Fosun will continue to increase investment in biopharmaceuticals and focus on deepening and thoroughly developing its advantageous industries to secure a commanding global position. The interim results presentation was held in Shanghai this morning, with attendees including Chairman Guo Guangchang, Co-Chairman Wang Qunbin, Co-CEO Chen Qiyu, Co-CEO Xu Xiaoliang, CFO Gong Ping, along with numerous investors and analysts.&
SHANGHAI, Aug. 29, 2025 -- United Imaging Healthcare (SSE: 688271), a global leader in advanced medical imaging and radiotherapy equipment, has released its financial results for the first half of 2025, maintaining steady growth. The company's revenue and net profit attributable to ordinary shareholders after deducting non-recurring profit or loss reached CNY 6.02 billion and 0.97 billion for 2025H1, representing a year-over-year increase of 12.79% and 21.01% respectively. The company's revenue growth was primarily fueled by continuous launch of innovative high-end products, now widely
[ 메디채널 김갑성 기자 ] Strategic Move Positions YD Bio Limited for Accelerated Innovation and Market Expansion Trading of common stock and warrants of the new public company, YD Bio Limited, is expected to commence on the Nasdaq Global Market on August 29, 2025, under the ticker symbols "YDES" and "YDESW" NEW YORK, Aug. 29, 2025 -- YD Bio Limited ("YD Bio Ltd" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful completio
DALLAS, Aug. 29, 2025 -- At Taiwan Expo USA 2025 in Dallas, the Smart Healthcare Pavilion, organized by the International Trade Administration (TITA) and the Taiwan External Trade Development Council (TAITRA), highlighted Taiwan's accelerating role in global digital health innovation. The pavilion brought together leading organizations introducing new approaches across telemedicine, artificial intelligence (AI), precision medicine, and next-generation medical services, as reported by GeneOnline. One key highlight was CancerFree Biotech Ltd., which has advanced precision oncolog
CHANGCHUN, China, Aug. 29, 2025 -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in life sciences, and JCBio Co., Ltd. ("JCBio"), a leading South Korean biotechnology company, have signed a Memorandum of Understanding (MoU) to launch the DCS Lab Project, a landmark collaboration. The initiative aims to accelerate multi-omics research, novel sequencing applications, precision medicine, clinical translation, and AI-driven data insights in South Korea. By combining MGI's advanced omics technologies with